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Abstract
It is widely accepted that most colorectal cancers (CRCs) arise from colorectal adenomas (CRAs), but transcriptomic data
characterizing the progression from colorectal normal mucosa to adenoma, and then to adenocarcinoma are scarce. These
transition steps were investigated using microarrays, both at the level of gene expression and alternative pre-mRNA
splicing. Many genes and exons were abnormally expressed in CRAs, even more than in CRCs, as compared to normal
mucosae. Known biological pathways involved in CRC were altered in CRA, but several new enriched pathways were also
recognized, such as the complement and coagulation cascades. We also identified four intersectional transcriptional
signatures that could distinguish CRAs from normal mucosae or CRCs, including a signature of 40 genes differentially
deregulated in both CRA and CRC samples. A majority of these genes had been described in different cancers, including
FBLN1 or INHBA, but only a few in CRC. Several of these changes were also observed at the protein level. In addition, 20% of
these genes (i.e. CFH, CRYAB, DPT, FBLN1, ITIH5, NR3C2, SLIT3 and TIMP1) showed altered pre-mRNA splicing in CRAs. As a
global variation occurring since the CRA stage, and maintained in CRC, the expression and splicing changes of this 40-gene
set may mark the risk of cancer occurrence from analysis of CRA biopsies.
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Introduction
Colorectal cancer (CRC) is one of the most prevalent cancers in
developed countries, and is a major leading cause of cancer-related
mortality worldwide. The most common type of CRC is
adenocarcinoma (.95%), which is an invasive neoplasm of the
glandular epithelium of the colon or rectum. It is accepted that
adenocarcinomas may likely arise from colorectal adenomas
(CRAs), as inferred from specific phenotypic features, such as size
and histology.
Colorectal lesions are classified at endoscopy as non-polypoid
(flat) and polypoid, which are separated into tubular, tubulovillous
or villous, with different grades of dysplasia. CRAs are often
referred to as adenomatous polyps that represent the lesions most
frequently associated with neoplastic outcome, and it was shown
that their removal was linked to a decrease in the incidence of
CRC [1]. While tubular adenomas are the most common, villous
adenomas are the least frequent, but they may transform into
cancer with high frequency [2]. In addition, patients with previous
multiple polyps had adenomas with advanced pathological
features [3].
Several driver mutations have been identified during the
progression from CRA to CRC [4], together with other molecular
events, such as microRNA modulation [5] or pre-mRNA splicing
alterations [6]. In addition, several gene expression profiles have
been reported in CRC [7,8]. Some studies also surveyed gene
expression in CRA, and analyzed the lineage with CRC
[9,10,11,12,13,14]. Nevertheless, most analyses were performed
from a limited number of CRA samples. Moreover, only a few
studies have looked at the genome-wide alternative pre-mRNA
splicing profiles of CRA samples [15] and their link with CRC,
even though alternative splicing occurs for an estimated 90% of
genes in the human genome [16].The aim of this study was to
analyze, with microarrays, gene expression and alternative splicing
in CRAs, in comparison with normal mucosae, but also with
CRCs. We report here a comprehensive picture of the modifica-
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tions that occurred in CRAs, some of which were specific for
CRAs, while others were shared in CRCs. Importantly, we
identified a 40-gene set (32 down- and 8 up-regulated genes), from
an intersectional analysis of side-by-side comparisons, considering
normal mucosae, CRAs and CRCs, that could mark the main
regulatory events characterizing the stepwise progression in
colorectal cancer.
Materials and Methods
Tissue Sample Processing
A written informed consent form was elaborated together with
the Ethics Committee of Brest University Hospital (headed by Pr.
J.M. Boles). Patients signed the form, which was returned to the
Anatomy and Pathology department of Brest University Hospital.
Hence, this study was approved by the Ethics committee of Brest
University Hospital. Colon or rectum biopsy samples were
obtained after surgical removal. The samples were then processed
anonymously. The tissue fragments derived from biopsies were
stored in RNAlater (Ambion, France): 55 CRAs, 25 CRCs and 27
colorectal normal mucosae (NOR; paired with CRAs or CRCs)
were collected between 2006 and 2012, the majority as of 2009.
From CRA or CRC biopsies, a surface fragment was collected
from the tumor region, comprising on average 90% tumor cells,
5% lymphocytes and 5% stromal cells. These percentages were
very homogenous between independent samples. Three subgroups
(A1, A2 and A3) of CRAs could be distinguished according to
histological data. Detailed patient information is presented in
Table 1 and Table S1. DNA and total RNA were extracted with
the AllPrep DNA/RNA Mini kit (Qiagen, Courtabœuf, France)
from homogenized tissue samples (20 mg), according to the
manufacturer’s instructions. RNA purity and integrity were
determined by measuring the optical density ratio (A260/A280)
and the RNA integrity number (RIN) was obtained using the RNA
6000 Nano LabChip (Agilent, Massy, France) and the 2100
Bioanalyzer (Agilent). Only RNA samples with a 28S/18S ratio .
1.0 and RIN $7.0 were used for microarray analyses.
Whole-Genome Microarray
An analysis of 55 RNA samples derived from colorectal tissue,
consisting of three sample groups (NOR, CRA and CRC) with
varying numbers of biological replicates, was performed on 44k
Whole Human Genome microarrays (Agilent) that contain 41,093
probes, providing full coverage of human transcripts. Double-
stranded cDNA was synthesized from 500 ng of total RNA using
the Quick Amp Labeling kit, One-color, as instructed by the
manufacturer (Agilent). Labeling with cyanine3-CTP, fragmenta-
tion of cRNA, hybridization, and washing were performed
according to the manufacturer’s instructions (Agilent). The
microarrays were scanned and the data were extracted with the
Agilent Feature Extraction Software.
Gene Expression Analysis
Raw gene expression data were imported into the GeneSpring
GX 11.0.2 software program (Agilent). Side-by-side comparisons
were performed for gene expression alterations: CRC vs. paired
NOR, CRA vs. NOR, and CRC vs. CRA. Genes with missing
values in more than 25% of the samples were excluded from the
analysis. These data have been deposited in NCBI’s Gene
Expression Omnibus and are accessible through GEO Series
accession numbers GSE50114, GSE50115 and GSE50117. A 2-
fold cut-off difference was applied to select the up- and down-
regulated genes (P-value #0.01 by t-test with Benjamini-Hochberg
false discovery rate, FDR). Hierarchical clustering of the
expression data was performed using Euclidean distance with
average linkage.
Gene Set Enrichment Analysis
The publicly available software, Database for Annotation,
Visualization and Integrated Discovery [17], was used to analyze
the gene set enrichment in colorectal lesions. A 2-fold cut-off
difference was applied to select the list of deregulated genes (P-
value #0.01 by t-test with FDR). Only the pathways from the
Kyoto Encyclopedia of Genes and Genomes (KEGG) will be
described [18].
Alternative Splicing Analysis
A pooled RNA, assayed in duplicate, from 3 colorectal normal
mucosae and 24 CRA RNA samples were analyzed on Human
Exon 1.0 ST arrays (Affymetrix, Paris, France), which enabled
analysis of both gene expression and alternative splicing.
Microarray hybridization was performed at the Curie Institute
facility (Paris, France). The raw data were analyzed by GenoSplice
technology. These data are accessible through GEO Series
accession number GSE50592. A 1.5-fold cut-off difference was
applied to select the up- and down-regulated genes and exons (P-
value #0.05).
Real-Time Polymerase Chain Reaction Validation
As a validation step of microarray results, quantitative RT-PCR
was performed on three groups (NOR, CRA and CRC) of at least
Table 1. Characteristics of colorectal biopsy samples used in the present study.
CRA
Group Subgroup A1 Subgroup A2 Subgroup A3 Out-of-Class CRC NOR
Agilent Whole Human
Genome Microarray
Number of Samples 9 13 15 0 9 9
Gender (male/female) (6/3) (10/3) (11/4) (5/4) (5/4)
Mean Age (range, years) 73 (58–92) 63 (52–77) 64 (46–88) 71 (48–92) 71 (48–92)
Affymetrix Human
Exon 1.0 ST Array
Number of Samples 7 7 9 1 0 0
Gender (male/female) (2/5) (6/1) (6/3) (0/1)
Mean Age (range, years) 71 (58–84) 68 (52–92) 62 (46–82) 50
Abbreviations: NOR: colorectal normal mucosa; CRA: colorectal adenoma; CRC: colorectal cancer.
doi:10.1371/journal.pone.0087761.t001
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8 samples, including some of the samples hybridized on
microarrays, or on an independent set of 14 CRAs and 8 paired
tumor-normal CRC samples. Total RNA (200 ng) was used for
first-strand cDNA synthesis with the High-Capacity cDNA
Reverse Transcription kit (Applied Biosystems). Quantitative
RT-PCR was performed using the Power SYBR Green PCR
Master Mix (Applied Biosystems) according to the manufacturer’s
instructions with an ABI 7000 or 7300 real-time PCR system
(Applied Biosystems). All determinations were performed in
duplicate and normalized against beta-2-microglobulin as an
internal control gene. The results were expressed as the relative
gene expression using the DDCt method [19]. All of the tested
genes were selected based on the microarray analyses, in order to
validate the biological pathway enrichment and a gene signature
in CRAs and CRCs. The primer sequences and reaction
conditions will be provided upon request. In addition, a PCR
array setup (Qiagen) was used to analyze, in NOR and CRC
samples, the expression of genes with primers present among the
PCR array multiwell plates (Apoptosis, Cancer Pathway Finder,
Drug Metabolism, Lipoprotein Signaling and Cholesterol Metab-
olism, Wnt Signaling Pathway).
Results
Comparison of Colorectal Adenoma Morphological
Subgroups
Several mutational landmarks have been described in the
progression to colorectal cancer, such as KRAS, BRAF and PI3K
mutations [4,20], and were analyzed in our samples (Supporting
Information). In addition, the microsatellite instability status
(Supporting Information) was determined in 12 CRA samples,
but all were negative. The Vienna classification allowed to group
adenomas into two classes: a minor group of lower grade (3) with
11 (22%) samples and a major group of 40 (78%) samples of higher
grade (.3) (Table S1). This classification did not match with the
tubular/villous/tubulovillous lesion types, since CRAs with both
low grade and high grade dysplasia were evenly distributed into
the tubullovillous and tubular groups (only one CRA was from the
villous type). This separation in tubular, villous or tubulovillous
was therefore not adopted. We decided to rely on a precise
morphology analysis and applied an anatomical grouping, which
led to the distinction of three morphological subgroups: adenomas
with areas of micro-invasive adenocarcinomas (A1; 10 samples),
degenerated adenomas, i.e. adenomas with areas of in situ (intra-
mucosa) adenocarcinomas (A2; 17 samples), and adenomas with
areas of dysplasia (A3; 24 samples). In order to determine if CRAs
could also be distinguished by molecular means, a one-way
ANOVA was performed to compare CRA subgroups to CRC and
NOR groups, with ‘‘tissue type’’ as an ANOVA factor (data not
shown). The analysis revealed that CRA subgroups were very close
with one another. There was no difference between subgroups A2
and A3, and the maximum number of deregulated probes was
found for the subgroup A1 vs. subgroup A2 comparison (49
probes, corresponding to 0.12% of total number of probes, P-value
#0.01). Moreover, while the comparisons between CRA sub-
groups and normal mucosae showed the largest numbers of
distinctive probes (up to 4,382 probes in subgroup A2 vs. NOR),
the comparisons between CRA subgroups and CRCs showed the
smallest (up to 1,424 probes in CRC vs. subgroup A2). CRAs as a
whole were thus more distinct from normal mucosae than from
CRCs. The three CRA subgroups were also compared to each
other, and no difference was observed in side-by-side comparisons
(P-value of #0.01 by t-test with FDR). Consequently, CRAs were
considered collectively as a single group for further side-by-side
comparisons by Student’s t-test.
Gene Expression Profiling in Colorectal Lesions in
Comparison with Normal Mucosae
In order to identify genes that could participate in the
progression from normal mucosa to CRA, we performed a CRA
vs. NOR comparison, and found that 2,393 probes were
deregulated in CRAs ($2.0 fold-change (FC), P-value of #0.01
by t-test with FDR), corresponding to 32% up- and 68% down-
regulations. The CRC vs. NOR comparison showed that 1,805
probes were deregulated in CRCs ($2.0 FC, P-value #0.01 by
paired t-test with FDR), corresponding to 46% up- and 54%
down-regulations. The heat maps of the deregulated probes with a
fold-change $3.0 and a P-value #0.001 are shown in Figures 1A
(CRA vs. NOR) and 1B (CRC vs. NOR), and Figure S1 (CRA vs.
NOR, full image). Complete lists of the differentially expressed
probes in CRA vs. NOR and CRC vs. NOR are presented in
Tables S2 and S3, respectively. A set of deregulation events in
CRA vs. NOR was analyzed by quantitative RT-PCR, and the
validation rate of Agilent microarray results was 78% (50 out of 64
transcripts; Table S4). In addition, Qiagen PCR array experiments
were performed on an independent set of 96 CRC and 20 NOR
samples (from Brest tumor bank). Among the deregulated probes
in CRC vs. NOR on microarrays, 41 primer pairs corresponding
to the same genes that were present in the PCR arrays. Twenty-
eight were also deregulated in PCR arrays ($2.0 FC, P-value #
0.01), corresponding to 68% cross validation (Table S5).
The CRA vs. NOR comparison showed more differences than
the CRC vs. NOR comparison, and there were more down-
regulations (68% in CRA vs. 54% in CRC) than up-regulations
(32% in CRA vs. 46% in CRC). An intersectional analysis of probe
level alterations was performed (Figure 2A), showing a signature of
954 probes deregulated in both CRA and CRC samples as
compared to normal mucosae (Table S6 and Figure S2),
corresponding to 40% and 53% deregulated probes in CRA and
CRC, respectively. All commonly deregulated probes followed the
same type of variation in both comparisons, i.e. were up- or down-
regulated similarly.
Pathway Enrichment in Colorectal Lesions in Comparison
with Normal Mucosae
The KEGG pathway analysis showed 25 gene sets distinguish-
ing CRA from NOR, and 20 distinguishing CRC from NOR (P-
value #0.05; Table 2), considering deregulated probes with a 2-
fold cut-off (P-value #0.01 by t-test with FDR). The complement
and coagulation cascades, cytokine-cytokine receptor interaction,
and chemokine signaling pathways were among the top of
enriched pathways in CRA vs. NOR, while cell cycle and DNA
replication were pathways most affected in CRC vs. NOR,
according to the P-value. Seven pathways were enriched in both
CRA vs. NOR and CRC vs. NOR comparisons, among which the
p53 signaling pathway was part of already described enriched
pathways in CRA [14]. Nitrogen metabolism was also a
commonly enriched pathway between both analyses, and included
the carbonic anhydrases (CA1 and CA4) that were part of the most
down-regulated probes in CRA and CRC.
If a 1.1-fold cut-off difference instead of 2.0 was applied to select
deregulated probes (P-value #0.01), i.e. if all deregulated probes
were considered (5 733 probes), 18 gene sets instead of 25 were
altered in CRA vs. NOR according to KEGG (P-value #0.05;
Table S7). Only the complement and coagulation cascades
pathway was common between both the 18 and 25 gene lists.
Transcriptomics of Colon Cancer Progression
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Therefore, 17 new pathways were enriched in CRA, such as DNA
replication, cell cycle, spliceosome or mismatch repair.
Gene Expression Profiling in Colorectal Adenocarcinomas
in Comparison with Colorectal Adenomas
An analysis of differentially detected probes between CRC and
CRA identified 669 deregulated probes ($2.0 FC, P-value of #
0.01 by t-test with FDR), corresponding to 55% up- and 45%
down-regulations. The heat map of the deregulated probes with a
fold-change $3.0 and a P-value #0.001 is shown in Figure 1C.
The complete list of the differential probe signals in CRC vs. CRA
is presented in Table S8. The CRC vs. CRA comparison showed
fewer probe level differences with much lower fold-changes than
the CRC vs. NOR and CRA vs. NOR comparisons. The
intersectional analysis of probe signals showed a signature of 172
probes deregulated in CRC as compared to both CRA and NOR
samples (Figure 2B, Table S9 and Figure S3), corresponding to
26% deregulated probes in CRC vs. CRA, and less than 10%
deregulated probes in CRC vs. NOR. As these modifications were
not present in CRA, they could be markers of CRC aggressive-
ness.
Pathway Enrichment in Colorectal Adenocarcinomas in
Comparison with Colorectal Adenomas
The KEGG pathway analysis revealed five gene sets distin-
guishing CRC from CRA (P-value #0.05; Table 2), considering
deregulated probes with a 2-fold cut-off (P-value #0.01 by t-test
with FDR). Two enriched pathways were specific for the CRC vs.
CRA comparison: arginine and proline metabolism, and TGF-beta
signaling pathway that has been already described as an altered
pathway between CRA and CRC [9]. Moreover, the CRA vs.
NOR and CRC vs. CRA comparisons had three commonly
enriched pathways, among which focal adhesion and ECM-
receptor interaction were part of already reported pathways
Figure 1. Hierarchical clustering considering the gene expression in colorectal lesions. Heat map of the expression data was constructed
using Euclidean distance with average linkage. The heat map of the deregulated probes with a fold-change $3.0 and a P-value #0.001 is shown for
CRA vs. NOR (A; complete heat map in Figure S1), for CRC vs. NOR (B), and CRC vs. CRA (C).
doi:10.1371/journal.pone.0087761.g001
Figure 2. Venn diagrams of probe level alterations in colorectal lesions. An intersectional analysis of probe level alterations was performed.
Cut-off values were P-value #0.01 and fold-change $2. The CRA vs. NOR comparison showed the largest number of probe level changes (2,393
deregulated probes), while the CRC vs. CRA comparison showed the lowest (669 deregulated probes). The probes that showed alterations in two or in
the three comparisons were of interest. (A) Signature of 954 probes deregulated in both CRA and CRC lesions as compared to NOR. (B) Signature of
172 probes deregulated in CRC in comparison to both CRA and NOR. (C) Signature of 265 probes deregulated in CRC as compared to CRA, which
levels were already abnormal in CRA as compared to NOR. (D) Signature of 44 probes showing alterations in the three comparisons (CRA vs. NOR, CRC
vs. CRA and CRC vs. NOR). Abbreviations: NOR: colorectal normal mucosa; CRA: colorectal adenoma; CRC: colorectal cancer.
doi:10.1371/journal.pone.0087761.g002
Transcriptomics of Colon Cancer Progression
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Table 2. KEGG gene sets enriched in colorectal lesions.
KEGG Enriched Pathway P-value
Benjamini-
Hochberg
Fold
Enrichment
Number of
Genes in the
Pathway
Number of
Deregulated
Genes
Percentage of
Deregulated
Genes
Colorectal Adenoma vs. Normal
Complement and coagulation cascades 5.6E-08 1.0E-05 3.29 69 26 38%
Cytokine-cytokine receptor interaction 3.4E-05 3.1E-03 1.76 262 53 20%
Chemokine signaling pathway 5.0E-04 3.0E-02 1.77 187 38 20%
Viral myocarditis 2.1E-03 9.3E-02 2.21 71 18 25%
Drug metabolism 2.4E-03 8.4E-02 2.64 43 13 30%
Intestinal immune network for IgA production 2.7E-03 7.7E-02 2.49 49 14 29%
Hematopoietic cell lineage 3.3E-03 8.1E-02 2.03 86 20 23%
Focal adhesion 3.7E-03 8.1E-02 1.61 201 37 18%
Aldosterone-regulated sodium reabsorption 5.1E-03 9.7E-02 2.55 41 12 29%
Axon guidance 5.3E-03 9.1E-02 1.76 129 26 20%
Androgen and oestrogen metabolism 7.0E-03 1.1E-01 2.59 37 11 30%
Cell adhesion molecules (CAMs) 7.1E-03 1.0E-01 1.72 132 26 20%
Pentose and glucuronate interconversions 1.2E-02 1.6E-01 3.39 18 7 39%
ECM-receptor interaction 1.3E-02 1.5E-01 1.87 84 18 21%
Asthma 1.4E-02 1.5E-01 2.71 29 9 31%
Pathways in cancer 1.9E-02 1.9E-01 1.36 328 51 16%
Basal cell carcinoma 1.9E-02 1.9E-01 2.06 55 13 24%
Leukocyte transendothelial migration 2.5E-02 2.3E-01 1.63 118 22 19%
Colorectal cancer 2.7E-02 2.3E-01 1.77 84 17 20%
Folate biosynthesis 2.9E-02 2.3E-01 3.96 11 5 45%
Ascorbate and aldarate metabolism 3.7E-02 2.8E-01 3.08 17 6 35%
Sulfur metabolism 4.0E-02 2.8E-01 3.63 12 5 42%
Prion diseases 4.0E-02 2.8E-01 2.24 35 9 26%
Nitrogen metabolism 4.0E-02 2.7E-01 2.65 23 7 30%
p53 signaling pathway 4.2E-02 2.7E-01 1.80 68 14 21%
Colorectal Cancer vs. Normal
Cell cycle 2.2E-07 3.9E-05 2.96 125 29 23%
DNA replication 9.9E-06 8.9E-04 4.60 36 13 36%
Pentose and glucuronate interconversions 2.5E-04 1.5E-02 5.66 18 8 44%
Purine metabolism 7.0E-04 3.1E-02 2.08 153 25 16%
Oocyte meiosis 2.0E-03 6.9E-02 2.20 110 19 17%
p53 signaling pathway 2.0E-03 5.8E-02 2.62 68 14 21%
Drug metabolism 2.7E-03 6.6E-02 2.67 62 13 21%
Starch and sucrose metabolism 4.4E-03 9.4E-02 3.03 42 10 24%
Mismatch repair 7.1E-03 1.3E-01 3.88 23 7 30%
Nitrogen metabolism 7.1E-03 1.3E-01 3.88 23 7 30%
Ascorbate and aldarate metabolism 8.1E-03 1.4E-01 4.50 17 6 35%
Sulfur metabolism 1.1E-02 1.7E-01 5.31 12 5 42%
Pyramiding metabolism 1.5E-02 2.0E-01 2.01 95 15 16%
Progesterone-mediated acolyte maturation 1.5E-02 1.9E-01 2.07 86 14 16%
Drug metabolism 1.7E-02 1.9E-01 2.67 43 9 21%
Metabolism of xenobiotics by cytochrome P 1.7E-02 1.8E-01 2.34 60 11 18%
Androgen and estrogen metabolism 2.3E-02 2.3E-01 2.76 37 8 22%
Retinol metabolism 2.3E-02 2.2E-01 2.36 54 10 19%
Steroid hormone biosynthesis 2.5E-02 2.2E-01 2.49 46 9 20%
Glycine, serine and threonine metabolism 3.0E-02 2.5E-01 2.88 31 7 23%
Colorectal Cancer vs. Colorectal Adenoma
Transcriptomics of Colon Cancer Progression
PLOS ONE | www.plosone.org 6 February 2014 | Volume 9 | Issue 2 | e87761
enriched in colon carcinogenesis [21]. These pathways could play
an important role in the progression of CRC, because they were
enriched from NOR to CRA, and then from CRA to CRC.
Intermediate Signature of Progression from Colorectal
Adenoma to Colorectal Adenocarcinoma
The evidence for the progression from NOR to CRA, and then
to CRC, was investigated with an intersectional analysis of probe
level alterations. A signature of 265 probes, corresponding to 215
genes, was identified (Figure 2C, Table S10 and Figure S4), which
was coincidental in lists of the 2,393 and 669 deregulated probes,
corresponding to the CRA vs. NOR and CRC vs. CRA
comparisons, respectively. It included deregulated probes in
CRC vs. CRA, which were already distinct in the CRA vs.
NOR analysis. The distributions of up- and down-regulated events
in CRC vs. CRA were 69% and 31%, respectively. An enrichment
analysis of the signature of 265 probes was performed using
KEGG pathways, and revealed that 41 genes were part of eight
enriched gene sets, including focal adhesion, ECM-receptor
interaction or TGF-beta signaling pathway (Table S11). Moreover,
an intermediate gene expression signature of 44 probes (corre-
sponding to 40 genes) was identified (Figure 2D and Table 3),
which was coincidental in the three lists of deregulated probes, and
then was part of all signatures that we previously described
(signatures of 954, 172 and 265 probes). It corresponded to 8 up-
and 32 down-regulated genes in both CRA and CRC samples, as
compared to normal mucosae. Eight probes demonstrated
progressively increased signals from NOR to CRA, and then to
CRC; 23 probes revealed gradually decreased signals. In addition,
13 probes were less suppressed in CRC than in CRA, as compared
to NOR.
Classification of Colorectal Adenomas in Comparison
with Normal Mucosae and Colorectal Adenocarcinomas
A classification of the colorectal tissues was performed using
hierarchical clustering of probe signal alterations corresponding to
the four signatures previously described. Only two groups were
distinguished considering the signature of 954 probes (Figure S2):
one was composed of normal mucosae and the other contained a
mix of colorectal lesions. By contrast, the clustering considering
the signature of 172 probes allowed to distinguish the three types
of colorectal tissues (Figure S3): one group was only composed of
CRCs, and the other was divided into a CRA subgroup and a
NOR subgroup. Similarly, the clustering with the signature of 265
probes enabled to distinguish the three sample types (Figure S4),
but one group was only composed of CRAs, and the other
grouped together the NOR and CRC samples that were
distributed into two distinct subgroups. Finally, the signature of
44 probes showed that the majority of CRAs clustered with CRCs,
a few CRAs (showing the least affected histology) being grouped
with NOR samples (Figure 3). For the majority of samples, no
strict concordance between histological (morphological subgroups
or localization) and molecular data was recognized concerning the
distribution of CRAs into subgroups. Similarly, the specifics of
CRC clustering were not explained by tumor localization (Table
S1). Molecular data could thus give supplementary information to
classify the colorectal lesions.
Exon-Level Analysis in Colorectal Adenomas
A CRA vs. NOR comparison was performed on Human Exon
1.0 ST arrays (Affymetrix), and showed that 1,484 genes were
deregulated in CRA (590 up- and 894 down-regulated genes;$1.5
FC, P-value #0.05; Table S12). A corresponding heat map is
shown in Figure S5. A set of deregulated transcripts in CRA vs.
NOR was analyzed by quantitative RT-PCR, and the validation
rate of Affymetrix microarray results was 83% (24 out of 29
transcripts, also validated for the Agilent analysis). In addition, the
CRA vs. NOR comparison showed extensive changes in alterna-
tive splicing profiles: 1,852 exons were deregulated in CRA (862
up- and 990 down-regulated exons; $1.5 FC, P-value #0.05;
Table S13). A publicly available microarray expression data set
from 10 paired tumor-normal CRC samples [6] was downloaded
from the Affymetrix web site in order to compare alternative
splicing profiling in CRA and CRC. The CRA vs. NOR and CRC
vs. NOR comparisons had 100 deregulated exons in common.
While 47 up- and 47 down-regulated splicing events followed the
same type of variation in the two comparisons, few regulations
were opposite in CRA and CRC, corresponding to 6% of
common deregulated exons (data not shown). We found that 296
deregulated (102 up- and 194 down-regulated) probes in CRA vs.
NOR from the Agilent analysis showed deregulated exons in the
Affymetrix analysis (data not shown). A lot of genes that were part
of altered pathways had deregulated exons. Among the 40 genes of
the Agilent transcriptional signature of 44 probes, 8 (CFH, CRYAB,
DPT, FBLN1, ITIH5, NR3C2, SLIT3 and TIMP1), i.e. 20%, had
deregulated exons (Table S14).
Discussion
The aim of this study was to investigate, at the whole-
transcriptome level, the extent of variations that occur in human
colorectal adenomas in comparison to adenocarcinomas, taking
the normal epithelium as a reference. Many changes were
apparent in CRA vs. NOR, even more so than in CRC vs.
NOR. Hence, CRA, as a type of intermediary lesion, already
Table 2. Cont.
KEGG Enriched Pathway P-value
Benjamini-
Hochberg
Fold
Enrichment
Number of
Genes in the
Pathway
Number of
Deregulated
Genes
Percentage of
Deregulated
Genes
ECM-receptor interaction 5.6E-05 7.8E-03 4.12 84 13 15%
TGF-beta signaling pathway 7.9E-05 5.6E-03 3.98 87 13 15%
Focal adhesion 1.5E-04 7.2E-03 2.65 201 20 10%
Complement and coagulation cascades 3.9E-03 1.3E-01 3.47 69 9 13%
Arginine and proline metabolism 4.7E-02 7.4E-01 3.01 53 6 11%
The KEGG pathway analysis showed 25 gene sets distinguishing CRA from NOR, 20 distinguishing CRC from NOR, and five distinguishing CRC from CRA (P-value#0.05),
considering deregulated genes with a 2-fold cut-off difference (P-value #0.01 by t-test with FDR).
doi:10.1371/journal.pone.0087761.t002
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Table 3. List of the up- and down-regulated genes of the gene expression signature of 44 probes.
Colorectal Adenoma vs. Normal Colorectal Cancer vs. Normal
Colorectal Cancer vs. Colorectal
Adenoma
Gene Symbol Probe Name P-value Fold-Change Regulation P-value Fold-Change Regulation P-value Fold-Change Regulation
SCARA5 A_23_P94103 1.04E-14 11.54 down 1.11E-03 36.56 down 1.27E-03 3.17 down
IGHA2 A_23_P61042 7.04E-03 3.77 down 3.43E-03 21.85 down 7.54E-03 5.80 down
BEST2 A_23_P16225 4.59E-03 4.25 down 1.11E-03 20.25 down 9.80E-03 4.76 down
C6orf105 A_23_P156826 3.72E-03 2.78 down 1.86E-03 18.54 down 9.22E-05 6.66 down
FAM55D A_23_P320216 1.00E-02 2.25 down 3.65E-03 17.45 down 2.00E-05 7.76 down
DNASE1L3 A_23_P257993 2.08E-04 2.39 down 1.94E-03 12.77 down 8.39E-06 5.34 down
UGT1A6 A_23_P60599 2.65E-03 2.33 down 3.46E-03 10.89 down 1.43E-04 4.67 down
LRRC19 A_23_P364625 1.38E-07 3.55 down 6.01E-03 9.42 down 3.52E-03 2.65 down
IGJ A_23_P167168 5.24E-03 2.50 down 3.42E-03 8.87 down 2.42E-03 3.55 down
ISX A_32_P217140 3.53E-04 2.65 down 4.80E-03 8.32 down 2.19E-03 3.14 down
NR3C2 A_23_P392470 3.98E-06 2.58 down 6.39E-03 7.53 down 3.79E-04 2.92 down
SMPDL3A A_23_P72117 1.20E-06 3.08 down 1.90E-03 7.07 down 2.30E-03 2.29 down
HSD11B2 A_23_P14986 2.52E-06 2.64 down 1.16E-03 7.07 down 6.38E-05 2.68 down
RDH5 A_24_P218814 2.54E-03 2.22 down 8.51E-04 6.34 down 7.18E-04 2.85 down
SEPP1 A_23_P121926 3.11E-06 2.95 down 2.45E-03 6.27 down 6.02E-03 2.13 down
ITM2C A_24_P379820 3.47E-03 2.04 down 2.84E-03 5.85 down 1.14E-03 2.87 down
ITM2C A_24_P402690 5.68E-04 2.08 down 5.51E-03 5.62 down 3.14E-04 2.70 down
PBLD A_23_P149998 3.95E-05 2.35 down 9.07E-03 5.58 down 5.90E-03 2.38 down
PBLD A_24_P112395 1.11E-04 2.21 down 7.65E-03 5.31 down 3.69E-03 2.40 down
LOC400573 A_32_P515920 7.71E-06 2.50 down 1.24E-03 5.17 down 3.48E-03 2.06 down
ASAP3 A_23_P114689 5.04E-05 2.37 down 7.64E-04 5.03 down 2.44E-03 2.13 down
C1orf115 A_23_P160433 1.89E-04 2.23 down 4.35E-03 4.83 down 2.85E-03 2.16 down
C1orf115 A_24_P131173 8.42E-04 2.08 down 6.01E-03 4.46 down 3.10E-03 2.15 down
DPT A_23_P200741 6.20E-18 27.31 down 6.92E-03 5.36 down 3.56E-07 5.09 up
SLIT3 A_23_P58588 3.42E-14 12.05 down 8.11E-04 5.19 down 2.55E-03 2.32 up
CFHR3 A_23_P103256 8.67E-16 9.06 down 5.95E-03 4.02 down 3.63E-04 2.25 up
CFH A_23_P200160 3.65E-11 8.65 down 3.43E-03 3.90 down 6.86E-03 2.22 up
FBLN1 A_23_P433016 8.05E-13 12.99 down 5.53E-03 3.40 down 9.13E-05 3.82 up
CCDC80 A_23_P58082 7.18E-14 15.11 down 5.62E-03 3.35 down 5.61E-06 4.52 up
FBLN1 A_23_P211631 1.36E-11 13.36 down 7.13E-03 3.20 down 1.02E-04 4.18 up
SPARCL1 A_23_P113351 2.28E-11 6.11 down 6.48E-03 3.01 down 4.95E-03 2.03 up
CRYAB A_24_P206776 2.31E-15 5.69 down 2.93E-03 2.72 down 1.96E-04 2.09 up
VSIG4 A_23_P217269 3.01E-10 8.43 down 2.61E-03 2.65 down 3.99E-04 3.18 up
PLN A_23_P30614 2.07E-07 8.08 down 3.37E-03 2.61 down 6.24E-03 3.10 up
ITIH5 A_23_P411993 3.16E-12 5.07 down 6.28E-03 2.40 down 2.69E-04 2.11 up
DACT3 A_23_P360964 3.82E-12 6.29 down 9.46E-03 2.30 down 1.11E-04 2.73 up
INHBA A_23_P122924 1.66E-06 5.72 up 6.54E-04 41.06 up 1.22E-05 7.18 up
TRIB3 A_23_P210690 1.73E-04 3.17 up 1.45E-03 9.88 up 3.10E-03 3.11 up
JUB A_23_P54055 2.03E-08 4.24 up 1.11E-03 8.77 up 2.75E-03 2.07 up
PSAT1 A_23_P259692 4.48E-03 2.47 up 5.72E-03 6.95 up 1.47E-03 2.81 up
MYBL2 A_23_P143190 3.96E-05 2.40 up 8.37E-03 5.19 up 2.58E-03 2.16 up
SKA3 A_23_P340909 1.05E-04 2.15 up 1.86E-03 4.65 up 3.87E-04 2.16 up
UBE2S A_32_P184933 2.74E-05 2.01 up 1.70E-03 4.56 up 4.22E-05 2.27 up
TIMP1 A_23_P62115 3.34E-04 2.11 up 2.25E-03 4.39 up 4.62E-03 2.08 up
Signature of 44 probes corresponding to genes showing alterations in the three comparisons (CRA vs. NOR, CRC vs. CRA and CRC vs. NOR; $2.0 FC, P-value #0.01 by t-
test with FDR).
doi:10.1371/journal.pone.0087761.t003
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exhibited strong signs of alterations. From the molecular changes
evidenced in CRA, it is clear that CRAs are not merely
accumulating alterations that will all be found in CRCs. Possibly,
the evolution to CRCs follows a more strictly clonal expansion,
which may lead to select for gene changes important for clonal
growth while eliminating less relevant modifications. According to
this hypothesis, CRAs may have different outcomes, some evolving
towards cancer, while others could be prone to disappearance. We
identified four signatures distinguishing the types of colorectal
tissues, and showed that a 40-gene set could be of specific interest,
marking the molecular changes that distinguish the normal
mucosa from CRA and CRC. Importantly, several alternative
pre-mRNA splicing events were also characteristic of the CRA to
CRC progression.
Several genes implicated in CRC were deregulated in CRA vs.
NOR. The highest increases in probe levels included KIA1199 that
had already been found deregulated in CRA [22], or the matrix
metalloproteinase MMP7 which over-expression is known to
influence early colorectal carcinogenesis [23]. Fifteen gene sets,
such as those involved in cytokine-cytokine receptor interaction,
chemokine signaling pathway, or cell adhesion molecules, were
specific for CRA vs. NOR. Importantly, several new enriched
biological pathways were identified, among which the complement
and coagulation cascades pathway was the most significantly
affected in the Agilent analysis, and was also identified as altered in
the Affymetrix analysis (data not shown). This agrees with a recent
report suggesting that components from the coagulation cascade
could influence cancer progression [24].
A number of genes were also differentially expressed in CRC vs.
CRA. Most of these genes have not been described in previous
microarray studies, although several of the changes agreed to
previous reports, including variations in the expression levels of
AMN, THBS2, SPP1 or TIMP1 [25,26,27]. In addition, 58
probes (19 up- and 39 down-regulated) from the CRC vs. CRA
comparison were among a list of 248 probes previously identified
[11], including that for AURKA, which encodes a cell cycle-
regulated kinase involved in CRC [28], and was over-expressed in
CRC, as compared to CRA and NOR. In addition, among our
top deregulated probes, SPON2, RGS16, SFRP4 and CTHRC1
have already been found among the most up-regulated probes in
CRC as compared to CRA, and FAM55D, ATOH8, RETNLB,
ID4, UGT1A6, and VSIG2, among the most down-regulated
probes [11]. It was already shown that some of these genes were
deregulated in epithelial cancers or associated with, such as
SFRP4, SPON2 [29], RGS16 [30], or UGT1A6 [31].
Specific gene expression alterations in either type of colorectal
lesions were identified, thanks to intersectional analyses (Figure 2).
Firstly, 1,218 (51%) deregulated probes were specific for the NOR
to CRA transition, and then, could mark low-risk CRA, because
there was no link with CRC. Secondly, 723 (40%) deregulated
probes were specific for CRC vs. NOR, and then could mark
specifically CRC. Finally, 276 (41%) deregulated probes were
specific for the CRA to CRC transition. The latter probe set could
be interesting to define events specific for the final steps of cancer
progression.
The signature of 954 probes corresponded to genes showing
expression alterations in both CRA and CRC samples, as
compared to normal mucosae. As these deregulated probes in
CRC were also abnormally expressed in CRA, they were unlikely
candidate markers of the progression from CRA to CRC.
Figure 3. Hierarchical clustering (Euclidean, average linkage) considering the expression signature of 44 probes. Branches represent
individual colorectal samples. Different colors were used to identify the sample groups: red, group of normal mucosae (N: normal); green, group of
adenomas (A: adenoma); blue, group of adenocarcinomas (C: cancer). The first sample annotation corresponds to the sample group. The subgroups
of adenomas are specified: A1, adenomas with areas of micro-invasive adenocarcinomas; A2, adenomas with areas of intra-mucosa adenocarcinomas;
A3, adenomas with areas of dysplasia. The second sample annotation corresponds to the sample number.
doi:10.1371/journal.pone.0087761.g003
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Accordingly, the hierarchical clustering did not allow distinguish-
ing CRAs from CRCs. The signature of 172 probes, correspond-
ing to genes deregulated in CRC in comparison to both CRA and
NOR, could mark specifically CRC and, supporting this
hypothesis, the hierarchical clustering identified the CRCs as a
single group. The signature of 265 probes corresponding to genes
deregulated in CRC vs. CRA, which were already abnormally
expressed in CRA vs. NOR, was of specific interest because it
could mark the progression from NOR to CRA, and then to CRC.
A small number of studies have analyzed the lineage between
NOR, CRA and CRC, and the genes differentially expressed
between CRA and CRC [13,25,26,27]. One of these studies
identified, on an Asian population, an intermediate gene
expression signature composed of 463 deregulated probe sets
[13]. Twenty seven % (57 out of 215) of the transcripts from our
list of 265 probes were identified in this previous signature (45 up-
and 12 down-regulated). The limited overlap between both studies
could be related to differences between human populations, as
already alluded to in a previous study [32]. In order to narrow
down this signature of 265 probes, we considered the 44 probes
that showed alterations in the three comparisons (CRA vs. NOR,
CRC vs. CRA and CRC vs. NOR), and then, were part of all
signatures that we identified. The 44 probes corresponded to 8 up-
and 32 down-regulated transcripts in both CRA and CRC
samples, as compared to normal mucosae. At least 35 out of the 40
transcripts of the signature were previously described in cancer,
but only 17 were already associated with colorectal cancer.
Among the over-expressed transcripts in colorectal lesions,
INHBA has been already identified in the transition from CRA to
CRC [13], and its expression has been associated with different
cancers, especially with gastric cancer [33]. PSAT1 was over-
expressed in colon tumors, and may be a new target for CRC
therapy [34]. It was demonstrated that TIMP1 increased cell
proliferation [35], and may be a CRC candidate marker in serum
[36]. The MMP/TIMP system plays a major role in tumor
invasion and metastasis, and increased expression of MMPs and
TIMPs (observed in our analyses in CRA and CRC) occurred at
an early stage of colorectal neoplasia [37]. SKA3 was required for
the maintenance of chromosome cohesion in mitosis [38]. UBE2S
played a role in the promotion of mitotic exit [39], and JUB
encodes a cell cycle regulator that interacts with Aurora-A [40].
Among the down-regulated transcripts in colorectal lesions, 20
showed a gradual expression alteration from NOR to CRA, and
then, from CRA to CRC, and 12 showed an opposite regulation in
the two transition steps, i.e. were down-regulated in the NOR to
CRA step, and up-regulated in the CRA to CRC step, and then,
were less down-regulated in CRC than in CRA, as compared to
NOR. Among the transcripts with gradually decreased expression,
only UGT1A6 had been already identified [13]. SCARA5, which
was proposed as a tumor suppressor gene in hepatocellular
carcinoma [41], was down-regulated in various tumor samples
[42], and may play a role in colorectal carcinogenesis [43].
Reduction of NR3C2/MR expression was already described as a
potential early event involved in CRC progression [44]. Five
(CCDC80, DPT, FBLN1, PLN and VSIG4) out of 12 transcripts with
increased expression in CRC vs. CRA were already found to be
up-regulated in CRC as compared to CRA [13]. Reduction of
CCDC80 expression has been observed in colorectal carcinogenesis
[45]. FBLN1 was down-regulated in prostate cancer and in
hepatocellular cancer, in which it was proposed as a novel
candidate tumor suppressor [46]. CFH (complement factor H)
might be a novel diagnostic marker for human lung adenocarci-
noma [47]. DACT3 was identified as an epigenetic regulator of the
Wnt pathway in CRC [48]. ITIH genes were down-regulated in
multiple human solid tumors, including colon cancer, and may
represent a family of putative tumor suppressor genes [49].
SPARCL1 was associated with a poor prognosis in CRC, and might
be a valuable marker for early diagnosis in CRC [50].
The impact of the mRNA expression alteration on the protein
level was analyzed by western blotting for a few selected genes
among the 40-gene set in both CRA and CRC samples (Supporting
Information). The regulation of one up-regulated gene (TRIB3), that
was already described as a CRC biomarker [51], and four down-
regulated genes (DPT, HSD11B2, RDH5 and SMPDL3A) resulted in
a similar regulation of the proteins (Figure S6), showing the potential
of these genes as biomarkers. An expected heterogeneity in mRNA
and protein expression across colorectal lesions was observed (data
not shown), indicating that the expression analysis of these genes
could be used to classify CRAs as low- or high-risk to transform into
CRC. Nevertheless, it will require several more years to get an
appreciation of the functional links between our gene signatures and
cancer progression, as our tissue samples have been sampled mostly
less than 4 years ago.
Defects in alternative splicing have been implicated in cancer,
and alterations in the expression of genes involved in spliceosome
assembly were already described in precancerous breast lesions
[52]. Our results indicate that changes in splicing profiles in CRA,
possibly contributed by modifications in splicing factors, may also
be found in CRC, and could define a splicing signature set that
could mark the potential for CRA to evolve towards CRC. The
alternative splicing events of two genes (FBLN1 and ITIH5) from
the 40-gene set (Table S14) were confirmed by quantitative RT-
PCR in CRA vs. NOR. Specifically, we validated the over-
expression of exon 3 and exon e16 for FBLN1, and the over-
expression of the last exons 13 and 14 for ITIH5, in CRAs as
compared to normal mucosae (data not shown). Both fibulin-1
(encoded by FBLN1) and inter-alpha-trypsin inhibitor heavy chain
(encoded by ITIH5) are involved in extracellular matrix associa-
tions, and both are suppressed in many cancers, including colon
cancer, as a consequence of promoter methylation, making the
genes putative tumor suppressor genes. The roles played by these
alternative splice products occurring in CRAs will require further
investigations, together with the other alternative transcripts
detected.
In conclusion, our study showed that genes were differentially
expressed between colorectal adenomas and adenocarcinomas
but, also, to a large extent, between colorectal adenomas and the
normal epithelium. We could identify different gene expression
signatures, among which one (signature of 44 probes) could be
indicative of the CRA patients with the highest potential for
developing CRC. The observation that several splicing factors
were deregulated in CRA (and CRC) is certainly in line with the
recent observations showing that the pre-mRNA splicing machin-
ery may be profoundly remodeled during cancer progression, and
may, therefore, play a major role in cancer outcome [53]. Further
analyses will be required to determine if these modifications may
be predictive markers of the pathological evolution in CRC.
Finally, from a systems biology standpoint, it will also be
interesting to try to determine if our various gene expression
signatures are under some kind of coordination control. This
would allow deriving predictive indexes. At a practical level, such
indexes could be used to classify patients, at time of adenoma
ablation, according to their risk for developing CRC.
Supporting Information
Figure S1 Hierarchical clustering considering the gene
expression in colorectal adenomas. Heat map of the
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expression data was constructed using Euclidean distance with
average linkage. The complete heat map of the deregulated probes
with a fold-change $3.0 and a P-value #0.001 is shown for CRA
vs. NOR.
(JPG)
Figure S2 Hierarchical clustering (Euclidean, average
linkage) of the colorectal tissues considering the gene
expression signature of 954 probes. Branches represent
individual colorectal samples. Different colors were used to identify
the sample groups: red, group of normal mucosae (N: normal);
green, group of adenomas (A: adenoma); blue, group of
adenocarcinomas (C: cancer). The first sample annotation
corresponds to the sample group. The subgroups of adenomas
are specified: A1, adenomas with areas of micro-invasive
adenocarcinomas; A2, adenomas with areas of intra-mucosa
adenocarcinomas; A3, adenomas with areas of dysplasia. The
second sample annotation corresponds to the sample number. The
hierarchical clustering allows distinguishing normal mucosae from
colorectal lesions, but not adenomas from adenocarcinomas.
(JPG)
Figure S3 Hierarchical clustering (Euclidean, average
linkage) of the colorectal tissues considering the gene
expression signature of 172 probes. Branches represent
individual colorectal samples. Different colors were used to identify
the sample groups: red, group of normal mucosae (N: normal);
green, group of adenomas (A: adenoma); blue, group of
adenocarcinomas (C: cancer). The first sample annotation
corresponds to the sample group. The subgroups of adenomas
are specified: A1, adenomas with areas of micro-invasive
adenocarcinomas; A2, adenomas with areas of intra-mucosa
adenocarcinomas; A3, adenomas with areas of dysplasia. The
second sample annotation corresponds to the sample number. The
hierarchical clustering allowsdistinguishing adenocarcinomas from
normal mucosae and adenomas.
(JPG)
Figure S4 Hierarchical clustering (Euclidean, average
linkage) of the colorectal tissues considering the gene
expression signature of 265 probes. Branches represent
individual colorectal samples. Different colors were used to identify
the sample groups: red, group of normal mucosae (N: normal);
green, group of adenomas (A: adenoma); blue, group of
adenocarcinomas (C: cancer). The first sample annotation
corresponds to the sample group. The subgroups of adenomas
are specified: A1, adenomas with areas of micro-invasive
adenocarcinomas; A2, adenomas with areas of intra-mucosa
adenocarcinomas; A3, adenomas with areas of dysplasia. The
second sample annotation corresponds to the sample number. The
hierarchical clustering allows distinguishing the three types of
colorectal tissues.
(JPG)
Figure S5 Hierarchical clustering by distance to mean
for the Affymetrix analysis. Twenty four adenoma samples
(polyps) were compared to a pool of normal mucosa sample
analyzed in duplicate. The hierarchical clustering allows distin-
guishing the two types of colorectal tissues.
(JPG)
Figure S6 Western blot analysis of NOR, CRA and CRC
samples. HSD11B2, SMPDL3A, RDH5, Dermatopontin (DPT)
and TRIB3 protein levels were analyzed in colorectal adenomas
and adenocarcinomas by western blotting. The mRNA levels were
analyzed in colorectal lesion samples by quantitative RT-PCR
(data not shown), and also validated the results of the AgilentTM
microarrays.
(JPG)
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